Olatoyosi Odenike to CD47 Antigen
This is a "connection" page, showing publications Olatoyosi Odenike has written about CD47 Antigen.
Connection Strength
0.233
-
Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy. Leuk Lymphoma. 2024 Jun; 65(6):864-867.
Score: 0.233